ALK‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors
- 7 October 2022
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 62 (2) , 75-84
Abstract
Anaplastic lymphoma kinase (ALK) fusions are oncogenic drivers in diverse cancer types. Although well established in inflammatory myofibroblastic tumor (IMT) and epithelioid fibrous histiocytoma (EFH), ALK rearrangements also occur in the emerging family of kinase fusion‐positive mesenchymal neoplasms. We investigated 9 ALK‐rearranged mesenchymal neoplasms (exclusive of IMT and EFH) arising in 6 males and 3 females with a wide age range of 10 to 78 years old (median 42 years). Tumors involved superficial and deep soft tissue (6) and viscera (3). Three were myxoid or collagenous low‐grade paucicellular tumors with haphazardly arranged spindled cells. Three were cellular tumors with spindled cells in intersecting short fascicles or solid sheets. Three cases consisted of uniform epithelioid cells arranged in nests or solid sheets, with prominent mitotic activity and necrosis. Band‐like stromal hyalinization was present in 6 cases. All tumors expressed ALK; four were positive for S100 and five were positive for CD34, while all were negative for SOX10. By targeted RNA sequencing, the breakpoints involved ALK exon 20; the 5′ partners included KLC1, EML4, DCTN1, PLEKHH2, TIMP3, HMBOX1, and FMR1. All but two patients presented with localized disease. One patient had distant lung metastases; another had diffuse pleural involvement. Of the six cases with treatment information, five were surgically excised [one also received neoadjuvant radiation therapy (RT)], and one received RT and an ALK inhibitor. Of the four patients with follow‐up (median 5.5 months), one remained alive with stable disease and three were alive without disease. We expand the clinicopathologic spectrum of ALK‐fused mesenchymal neoplasms, including a low‐grade malignant peripheral nerve sheath tumor‐like subset and another subset characterized by epithelioid and high‐grade morphology.Keywords
This publication has 46 references indexed in Scilit:
- A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid CarcinomaAmerican Journal of Surgical Pathology, 2015
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsCancer Discovery, 2014
- circlizeimplements and enhances circular visualization in RBioinformatics, 2014
- Mechanistic insight into ALK receptor tyrosine kinase in human cancer biologyNature Reviews Cancer, 2013
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Anaplastic large cell lymphoma, ALK-positiveCritical Reviews in Oncology/Hematology, 2012
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue OnlyPLOS ONE, 2012
- Epithelioid Inflammatory Myofibroblastic SarcomaAmerican Journal of Surgical Pathology, 2011
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Inflammatory Myofibroblastic TumorAmerican Journal of Surgical Pathology, 2007